Cargando…
Different Serotonergic Expression in Nevomelanocytic Tumors
The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835124/ https://www.ncbi.nlm.nih.gov/pubmed/24281111 http://dx.doi.org/10.3390/cancers2021166 |
_version_ | 1782292105228451840 |
---|---|
author | Naimi-Akbar, Clara Ritter, Markus Demel, Sasika El-Nour, Husameldin Hedblad, Mari-Anne Azmitia, Efrain C. Nordlind, Klas |
author_facet | Naimi-Akbar, Clara Ritter, Markus Demel, Sasika El-Nour, Husameldin Hedblad, Mari-Anne Azmitia, Efrain C. Nordlind, Klas |
author_sort | Naimi-Akbar, Clara |
collection | PubMed |
description | The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis. Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors. Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM. Furthermore, some of these latter cells expressed both 5-HT1AR and 5-HT2AR. The level of expression of 5-HT1AR at the junctional area was lower for SSM than for DN or BCN. As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined. Vessel immunoreactivity for 5-HT2A was more intense in SSM than in BCN tissue. Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM. These latter cells were also tryptase-positive, indicating that they are mast cells. Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection. |
format | Online Article Text |
id | pubmed-3835124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-38351242013-11-21 Different Serotonergic Expression in Nevomelanocytic Tumors Naimi-Akbar, Clara Ritter, Markus Demel, Sasika El-Nour, Husameldin Hedblad, Mari-Anne Azmitia, Efrain C. Nordlind, Klas Cancers (Basel) Article The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis. Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors. Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM. Furthermore, some of these latter cells expressed both 5-HT1AR and 5-HT2AR. The level of expression of 5-HT1AR at the junctional area was lower for SSM than for DN or BCN. As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined. Vessel immunoreactivity for 5-HT2A was more intense in SSM than in BCN tissue. Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM. These latter cells were also tryptase-positive, indicating that they are mast cells. Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection. Molecular Diversity Preservation International (MDPI) 2010-06-07 /pmc/articles/PMC3835124/ /pubmed/24281111 http://dx.doi.org/10.3390/cancers2021166 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Naimi-Akbar, Clara Ritter, Markus Demel, Sasika El-Nour, Husameldin Hedblad, Mari-Anne Azmitia, Efrain C. Nordlind, Klas Different Serotonergic Expression in Nevomelanocytic Tumors |
title | Different Serotonergic Expression in Nevomelanocytic Tumors |
title_full | Different Serotonergic Expression in Nevomelanocytic Tumors |
title_fullStr | Different Serotonergic Expression in Nevomelanocytic Tumors |
title_full_unstemmed | Different Serotonergic Expression in Nevomelanocytic Tumors |
title_short | Different Serotonergic Expression in Nevomelanocytic Tumors |
title_sort | different serotonergic expression in nevomelanocytic tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835124/ https://www.ncbi.nlm.nih.gov/pubmed/24281111 http://dx.doi.org/10.3390/cancers2021166 |
work_keys_str_mv | AT naimiakbarclara differentserotonergicexpressioninnevomelanocytictumors AT rittermarkus differentserotonergicexpressioninnevomelanocytictumors AT demelsasika differentserotonergicexpressioninnevomelanocytictumors AT elnourhusameldin differentserotonergicexpressioninnevomelanocytictumors AT hedbladmarianne differentserotonergicexpressioninnevomelanocytictumors AT azmitiaefrainc differentserotonergicexpressioninnevomelanocytictumors AT nordlindklas differentserotonergicexpressioninnevomelanocytictumors |